Compounds and pharmaceutically acceptable salts are described compounds. It also describes Pharmaceutical compositions, Methods of treatment, Methods Of Synthesis and corresponding intermediaries. Suitable for the treatment of neurodegenerative and neurological diseases.Claim 1: a compound having the structure of formula (1) or a pharmaceutically acceptable Salt thereof, wherein: X is a heteroaryl 5 - 14 - 1 - 3 members containing heteroatoms； r u00b9 is Hydrogen, halogen, alkyl or cycloalkyl c u2081 u208b u2086, c u2083 u208b u2086, alquenilo C u2082 u208b u2086； where the said rent,Cycloalkyl or alquenilo is optionally substituted with one to three substituents each independently selected from the group consisting of FluorineHydroxyl and alkoxy c u2081 u208b u2086； is a c u2083 u208b u2086 cycloalkyl or an heterocicloalquilo 4 - 10 members； where cycloalkyl or heterocicloalquilo is optionally substituted with one to three substituents each independently selected from the group consisting of Hal u00f3geno and alkyl c u2081 u208b u2086； r u00b2 u1d43 and r u00b2 u1d47 for each occurrence is independently Hydrogen, cyano, Fluorine, cf u2083,C u2081 u208b u2086 alquenilo c u2082 u208b u2086, alkyl, cycloalkyl c u2083 u208b u2086, bicicloalquilo c u2084 u208b u2088, alquinilo c u2082 u208b u2086 or phenyl； where the alquenilo, alkyl, cycloalkyl, bicicloalquilo, alquinilo is optionally substituted phenyl or with one to three each way Selected substituents Independent from the group consisting of Ciano,Rent c u2081 u208b u2083 and r u00b2 u1d43 r u00b2 u1d47 or Fluorine； and together with the carbon to which together form a cycloalkyl of 3 - to 5 - member optionally substituted with one to three of r u2078； r u00b3 is Hydrogen, halogen, alkyl c u2081 u208b u2086, alquenilo c u2082 u208b u2086, - (C (r u00b9 u2070) u2082 u209c (cycloalkyl) - c u2083 u208b u2086) - (C (r u00b9 u2070) u2082 u209c (heterocicloalquilo) - 4 - (10 members) - C (r u00b9 u2070) u2082 u209
